Tumor infiltrating immune cells (TIICs) as a biomarker for prognosis benefits in patients with osteosarcoma
Background: Osteosarcoma is a rare malignant bone tumor in adolescents and children. Poor prognosis has always been a difficult problem for patients with osteosarcoma. Recent studies have shown that Tumor infiltrating immune cells (TIICs) are associated with the clinical outcome of osteosarcoma patients. The aim of our research was to construct a risk score model based on TIICs to predict the prognosis of patients with osteosarcoma.
Methods: CIBERSORT algorithm was used to calculate the proportion of 22 TIICs in osteosarcoma samples. Kaplan-Meier curves were drawn to investigate the prognostic value of 22 TIICs. Forward stepwise approach was used to screen a minimal set of immune cells. Multivariate Cox PHR analysis was performed to construct an immune risk score model.
Results: Osteosarcoma samples with CIBERSORT output p value less than 0.05 were selected for research. Kaplan-Meier curves indicated that naive B cells (p=0.047) and Monocytes (p=0.03) in osteosarcoma are associated with poor prognosis. An immune risk score model was constructed base on eight immune cells, and the ROC curve showed that the immune risk score model is reliable in predicting the prognosis of patients with osteosarcoma (AUC=0.724). Besides, a nomogram model base on eight immune cells was constructed to predict the survival rate of patients with osteosarcoma.
Conclusions: TIICs are closely related to the prognosis of osteosarcoma. The immune risk score model based on TIICs is reliable in predicting the prognosis of osteosarcoma.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Posted 10 Jun, 2020
On 21 Oct, 2020
On 10 Sep, 2020
On 19 Aug, 2020
On 16 Aug, 2020
Received 27 Jul, 2020
Received 27 Jul, 2020
On 06 Jul, 2020
On 28 Jun, 2020
Invitations sent on 26 Jun, 2020
On 08 Jun, 2020
On 07 Jun, 2020
On 07 Jun, 2020
On 04 Jun, 2020
Posted 10 Jun, 2020
On 24 Sep, 2020
On 23 Sep, 2020
On 23 Sep, 2020
Tumor infiltrating immune cells (TIICs) as a biomarker for prognosis benefits in patients with osteosarcoma
Posted 10 Jun, 2020
On 21 Oct, 2020
On 10 Sep, 2020
On 19 Aug, 2020
On 16 Aug, 2020
Received 27 Jul, 2020
Received 27 Jul, 2020
On 06 Jul, 2020
On 28 Jun, 2020
Invitations sent on 26 Jun, 2020
On 08 Jun, 2020
On 07 Jun, 2020
On 07 Jun, 2020
On 04 Jun, 2020
Posted 10 Jun, 2020
On 24 Sep, 2020
On 23 Sep, 2020
On 23 Sep, 2020
Background: Osteosarcoma is a rare malignant bone tumor in adolescents and children. Poor prognosis has always been a difficult problem for patients with osteosarcoma. Recent studies have shown that Tumor infiltrating immune cells (TIICs) are associated with the clinical outcome of osteosarcoma patients. The aim of our research was to construct a risk score model based on TIICs to predict the prognosis of patients with osteosarcoma.
Methods: CIBERSORT algorithm was used to calculate the proportion of 22 TIICs in osteosarcoma samples. Kaplan-Meier curves were drawn to investigate the prognostic value of 22 TIICs. Forward stepwise approach was used to screen a minimal set of immune cells. Multivariate Cox PHR analysis was performed to construct an immune risk score model.
Results: Osteosarcoma samples with CIBERSORT output p value less than 0.05 were selected for research. Kaplan-Meier curves indicated that naive B cells (p=0.047) and Monocytes (p=0.03) in osteosarcoma are associated with poor prognosis. An immune risk score model was constructed base on eight immune cells, and the ROC curve showed that the immune risk score model is reliable in predicting the prognosis of patients with osteosarcoma (AUC=0.724). Besides, a nomogram model base on eight immune cells was constructed to predict the survival rate of patients with osteosarcoma.
Conclusions: TIICs are closely related to the prognosis of osteosarcoma. The immune risk score model based on TIICs is reliable in predicting the prognosis of osteosarcoma.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6